Novo Nordisk (CPSE:NOVO B) has won a Dutch court injunction against Ceban Ziekenhuisfarmacie, blocking production and distribution of an unapproved compounded semaglutide nasal spray in the Netherlands. The ruling determined that the compounded nasal spray infringed Novo Nordisk’s semaglutide patent, reinforcing the company’s intellectual property position across its flagship drug portfolio. The injunction limits the reach of non-approved competitor versions of semaglutide in the Dutch market, a meaningful development as compounded GLP-1 alternatives have proliferated globally. For investors, the Dutch ruling demonstrates that Novo Nordisk can actively use its patent portfolio to curtail unapproved compounded versions of semaglutide, which directly supports the long-term GLP-1 cash flow narrative. To assess the fuller investment case, analysts and investors will be watching whether Novo Nordisk can extend similar patent enforcement actions to other jurisdictions where compounded GLP-1 products remain a concern.